2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1457

Perioperative Management of Methotrexate and Tumor Necrosis Factor Inhibitor Combination Therapy in Rheumatoid Arthritis Patients
Abstract Number: 1332

Periostin Deficiency Exacerbates Joint Inflammation and Bone Destruction in Mouse Models of Rheumatoid Arthritis
Abstract Number: 1401

Persistence of Mast Cell-Rich Synovitis Is Associated with Lack of Response to Synthetic Disease Modifying Anti-Rheumatic Drugs in Patients with Early Rheumatoid Arthritis
Abstract Number: 953

Persistence of Pathogenic CD4 Memory T Cells Revealed through Cytometry Time of Flight in Juvenile Idiopathic Arthritic Patients with Disease Resurgence upon Withdrawal of Anti-TNFA Biologics
Abstract Number: 1001

Persistence, Discontinuation, and Switching Patterns Among Ankylosing Spondylitis Patients Newly Initiating Biologic Therapy
Abstract Number: 1552

Persistency of Tumor Necrosis Factor Inhibitor Therapy in US Patients with Ankylosing Spondylitis: Data from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Abstract Number: 1890

Persistent Fracture Reduction with Abaloparatide-SC (TYMLOS™) Followed By 24 Months of Alendronate
Abstract Number: 2892

Persistently Frequent Emergency Department (ED) Utilization Among Systemic Lupus Erythematosus (SLE) Patients
Abstract Number: 1259

Perspectives of Young People with Juvenile Idiopathic Arthritis, Their Caregivers, and Health Care Providers on Transition to Adult Care: Informing Development of a Transition Toolkit
Abstract Number: 915

Pesticide Exposure and Risk of Systemic Lupus Erythematosus in an Urban Population of Predominantly African-American Women
Abstract Number: 801

PET-CT Findings and Clinical Outcomes in Takayasu Arteritis – Does 18F-Fluorodeoxyglucose Uptake in Arteries Predict Relapses?
Abstract Number: 2868

Pharmacodynamic Analysis of Whole Blood Gene Expression over 2 Years in a Phase IIIb Head-to-Head Trial of Abatacept and Adalimumab in Patients with RA
Abstract Number: 2565

Pharmacodynamic Modeling of BTK Occupancy Versus Efficacy in Ra and SLE Models Using the Novel Specific BTK Inhibitor Evobrutinib
Abstract Number: 1893

Pharmacokinetics (PK), Pharmacodynamics (PD), and Proposed Dosing of Oral Janus Kinase (JAK)1 and JAK2 Inhibitor Baricitinib in Patients with IFN-Mediated Autoinflammatory Diseases (AIDs)
Abstract Number: 1752

Pharmacokinetics of Rituximab and Clinical Outcomes in Patients with ANCA-Associated Vasculitis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].